ITHACA, N.Y., Dec. 16 /PRNewswire/ -- Advion BioSciences Inc., a leading provider of mass spectrometry services and products to the pharmaceutical industry, today announced the signing of a $9 million, three-year contract to provide bioanalytical services for an unnamed, top-ten pharmaceutical company.
Under the terms of the agreement, Advion will provide scientists and instrumentation to support the pharmaceutical client's bioanalytical method development, method validation, and sample analysis programs. The agreement also provides the pharmaceutical client an option to increase its level of committed resources during the life of the contract, and to secure resources at a time when outsourcing is a major strategic imperative for the drug development industry.
According to Stephen Lowes, Ph.D., Advion's vice president of bioanalysis, besides offering efficiencies in resource planning and utilization, the agreement allows scientists from both companies to collaborate more effectively on a daily basis, further strengthening a relationship based on Advion's core values of quality, timeliness and exceptional service.
"This contract is the first of its kind for Advion and is a testament to our hard work and commitment to this client. Our agreement will allow us to focus our teams, resulting in better service for a very valuable client," Dr. Lowes said. "The contract offers a resource model that could be extended to other clients in an environment where top-tier bioanalytical experience is in high demand."
Founded in 1993, Advion BioSciences Inc., of Ithaca, N.Y., is a leading provider of mass spectrometry services to the pharmaceutical industry, and a developer of automated, chip-based technology designed to boost the sensitivity, data quality and sample throughput for electrospray mass spectrometers. The privately held company operates one of the world's largest LC/MS contract research facilities. For more information visit http://www.advion.com/.
Advion BioSciences Inc.